Pacer Advisors
RPRX icon

Pacer Advisors’s Royalty Pharma RPRX Stock Holding History

Pacer Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.1M Sell
689,194
-64,855
-9% -$2.84M 0.09% 229
2025
Q4 		$29.1M Buy
754,049
+192,463
+34% +$7.34M 0.07% 249
2025
Q3 		$19.8M Buy
+561,586
New +$20.3M 0.05% 321
2024
Q3 		– Sell
-36,353
Closed -$959K – 2675
2024
Q2 		$959K Buy
36,353
+13,538
+59% +$375K ﹤0.01% 1333
2024
Q1 		$693K Buy
22,815
+14,578
+177% +$430K ﹤0.01% 1410
2023
Q4 		$231K Buy
8,237
+4,177
+103% +$115K ﹤0.01% 1856
2023
Q3 		$110K Buy
+4,060
New +$121K ﹤0.01% 2140

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Pacer Advisors's RPRX Position: Q1 2026 in Review

Pacer Advisors reduced its Royalty Pharma (RPRX) stake by 8.6% in Q1 2026, selling an estimated $2.84M and leaving 689,194 shares worth $33.1M. The position accounts for 0.09% of the portfolio, ranked #229.

Pacer Advisors first reported a position in RPRX in Q3 2023 and has held it in 7 quarters since. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Pacer Advisors held 689,194 shares of Royalty Pharma worth $33.1M as of Q1 2026.
  • Pacer Advisors sold 64,855 Royalty Pharma shares in Q1 2026, an estimated $2.84M.
  • Royalty Pharma made up 0.09% of Pacer Advisors's portfolio in Q1 2026, its #229 holding.
  • Pacer Advisors first reported a position in Royalty Pharma in Q3 2023 and has held it in 7 quarters since.
  • 587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Pacer Advisors's 13F filing for Q1 2026, filed 6 May 2026.